Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Minerva Neurosciences (NASDAQ: NERV) announced its participation in the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:55 p.m. GMT (7:55 a.m. EST). The presentation will be available as a live webcast and can be accessed through the company’s investor relations website. Minerva focuses on developing innovative therapies for CNS disorders, with key compounds including roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. For further details, visit the company's website.

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).

The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.

About Minerva Neurosciences

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

FAQ

When is Minerva Neurosciences participating in the Jefferies Virtual London Healthcare Conference?

Minerva Neurosciences will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:55 p.m. GMT.

Where can I watch the Minerva Neurosciences conference presentation?

The presentation will be webcast live and archived on the investor relations section of Minerva Neurosciences' website.

What is the stock symbol for Minerva Neurosciences?

The stock symbol for Minerva Neurosciences is NERV.

What are the main compounds developed by Minerva Neurosciences?

Minerva's key compounds include roluperidone for schizophrenia, seltorexant for insomnia and MDD, and MIN-301 for Parkinson's disease.

What is the focus of Minerva Neurosciences?

Minerva Neurosciences focuses on developing innovative therapies to treat central nervous system (CNS) disorders.